Author

Jolien De Rechter

Observed name: J De Rechter

OpenAlex ID: A5115980934

The Effect of Dose Intensification After Secondary Loss of Response to Ustekinumab in Crohn’s Disease: Results of the REScUE Study

2026 · Peter Bossuyt, Jean-Francois Rahier, et al. · Gastroenterology · 5

P1008 Subcutaneous infliximab in IBD patients previously treated with an optimized intravenous infliximab dosing schedule: preliminary results on expectations and satisfaction of switching from intravenous to subcutaneous infliximab

2025 · A Moens, T Holvoet, et al. · Journal of Crohn s and Colitis · 1

Building sustainable IBD clinical research units: a practical toolbox emerging from a Belgian multi-stakeholder initiative

2026 · Ingrid Arijs, Leonie Govaerts, et al. · Journal of Crohn s and Colitis

Mo1528 WILLINGNESS TO SWITCH FROM OPTIMIZED INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN IBD PATIENTS: BASELINE CHARACTERISTICS FROM THE AMARETTO TRIAL.

2026 · Annick Moens, Tom Holvoet, et al. · Gastroenterology

Mo1528 WILLINGNESS TO SWITCH FROM OPTIMIZED INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN IBD PATIENTS: BASELINE CHARACTERISTICS FROM THE AMARETTO TRIAL.

2026 · Annick Moens, Tom Holvoet, et al. · Gastrointestinal Endoscopy

P1157 Willingness to switch from optimized intravenous to subcutaneous infliximab in IBD: baseline characteristics from the AMARETTO trial

2026 · A Moens, T Holvoet, et al. · Journal of Crohn s and Colitis

Su1876: PRELIMINARY RESULTS ON EXPECTATIONS AND SATISFACTION OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS PREVIOUSLY TREATED WITH AN OPTIMIZED INTRAVENOUS INFLIXIMAB DOSING SCHEDULE.

2025 · Tom Holvoet, Annick Moens, et al. · Gastroenterology

Works count: 7

Citation count: 6

H-index: 1

I10-index: